Home
About
FAQ
History (14)
Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Session III: Mechanisms of age-related cognitive change and targets for intervention: inflammatory, oxidative, and metabolic processes.
Carboxypeptidases
Changes in NIH review procedures: strengths and weaknesses.
See All 14 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Changes in NIH review procedures: strengths and weaknesses.
Adler KB, Abraham E. Changes in NIH review procedures: strengths and weaknesses. Am J Respir Crit Care Med. 2009 Aug 01; 180(3):197.
View in:
PubMed
subject areas
Biomedical Research
Humans
National Institutes of Health (U.S.)
Peer Review, Research
United States